MARCH研究首项头对头比较阿卡波糖和二甲双胍降糖疗效研究

2011-12-10 MedSci原创 MedSci原创

 卫生部中日友好医院杨文英教授介绍了中国新诊断2型糖尿病初始治疗方案探讨研究(MARCH)结果。   该研究为随机、前瞻性、多中心、开放、平行对照研究,将2型糖尿病患者随机分入阿卡波糖或二甲双胍组治疗24周,最终完成病例数为657例。结果显示,两类药物降低HbA1c水平相当。二甲双胍降低空腹血糖效果较好;在降低餐后2小时血糖方面,阿卡波糖优于二甲双胍。阿卡波糖减轻体重效果优于二甲双胍。接受两种药

 卫生部中日友好医院杨文英教授介绍了中国新诊断2型糖尿病初始治疗方案探讨研究(MARCH)结果。

  该研究为随机、前瞻性、多中心、开放、平行对照研究,将2型糖尿病患者随机分入阿卡波糖或二甲双胍组治疗24周,最终完成病例数为657例。结果显示,两类药物降低HbA1c水平相当。二甲双胍降低空腹血糖效果较好;在降低餐后2小时血糖方面,阿卡波糖优于二甲双胍。阿卡波糖减轻体重效果优于二甲双胍。接受两种药物治疗患者的胃肠道不良事件发生率无显著差异。

  杨教授认为该研究初步结果令人振奋,后续结果将在2012年陆续公布。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1818705, encodeId=2bb61818e0546, content=<a href='/topic/show?id=601e981e766' target=_blank style='color:#2F92EE;'>#降糖疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98177, encryptionId=601e981e766, topicName=降糖疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 15 17:00:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949800, encodeId=67ee19498003e, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 30 09:00:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570693, encodeId=840915e0693ba, content=<a href='/topic/show?id=0b079e73206' target=_blank style='color:#2F92EE;'>#阿卡波糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97732, encryptionId=0b079e73206, topicName=阿卡波糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5615684900, createdName=jwf_2006, createdTime=Mon Dec 12 13:00:00 CST 2011, time=2011-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1818705, encodeId=2bb61818e0546, content=<a href='/topic/show?id=601e981e766' target=_blank style='color:#2F92EE;'>#降糖疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98177, encryptionId=601e981e766, topicName=降糖疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 15 17:00:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949800, encodeId=67ee19498003e, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 30 09:00:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570693, encodeId=840915e0693ba, content=<a href='/topic/show?id=0b079e73206' target=_blank style='color:#2F92EE;'>#阿卡波糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97732, encryptionId=0b079e73206, topicName=阿卡波糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5615684900, createdName=jwf_2006, createdTime=Mon Dec 12 13:00:00 CST 2011, time=2011-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1818705, encodeId=2bb61818e0546, content=<a href='/topic/show?id=601e981e766' target=_blank style='color:#2F92EE;'>#降糖疗效#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98177, encryptionId=601e981e766, topicName=降糖疗效)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=bioon1, createdTime=Fri Jun 15 17:00:00 CST 2012, time=2012-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949800, encodeId=67ee19498003e, content=<a href='/topic/show?id=92ed443582b' target=_blank style='color:#2F92EE;'>#头对头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44358, encryptionId=92ed443582b, topicName=头对头)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Fri Mar 30 09:00:00 CST 2012, time=2012-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570693, encodeId=840915e0693ba, content=<a href='/topic/show?id=0b079e73206' target=_blank style='color:#2F92EE;'>#阿卡波糖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97732, encryptionId=0b079e73206, topicName=阿卡波糖)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c5615684900, createdName=jwf_2006, createdTime=Mon Dec 12 13:00:00 CST 2011, time=2011-12-12, status=1, ipAttribution=)]